Expiring Patents, Uptick in Biotech Spending Could Spur qPCR-Based Dx, Tool Development

The combination of recently expired or soon-to-expire patents in the qPCR space, combined with recent increased financial stability in the biotech tools market, could help spur a proliferation of new PCR-based diagnostics and research tools in coming months, an expert in biotechnology patenting said at a qPCR scientific meeting held this week.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.